Intended Use

“MagQu” GFAP IMR Reagent is used to quantitatively measure glial fibrillary acidic protein(GFAP) in human fluid specimen, such as plasma, serum or CSF.
Use “MagQu” GFAP IMR Reagent only with the XacPro-S System (MagQu Co., Ltd.).

Introduction

Glial fibrillary acidic protein (GFAP) is the main constituent of the astrocytic cytoskeleton, which plays an important role in the structure and mobility of astrocytes and can affect astrocyte function. The amount of GFAP in the blood begins to rise in the early stages of Alzheimer's disease. Symptoms of astroglial cell deposition can be a sign of the onset of early events in AD. Therefore, GFAP can be used to predict the future onset of Alzheimer's disease, mild cognitive impairment, and changes in the structural features of brain MRI in the elderly. ^1,2

Principle of Test

“MagQu” GFAP IMR Reagent is designed for rapid quantifying GFAP by ImmunoMagnetic Reduction (IMR). We conjugate antibody on the surface of around 50 nm-in-diameter Fe₃O₄ magnetic particles. When the antibodies on the surface bind with GFAP, the magnetic particles form clusters. Therefore, the ac susceptibility (Xac) of magnetic particles would be reduced in the adding ac magnetic field. By measuring the reduction of Xac, GFAP can be easily, rapidly and accurately quantified.³

References

1. Schiff L, Hadker N, Weiser S, Rausch C. A literature review of the feasibility of glial fibrillary acidic protein as a biomarker for stroke and traumatic brain injury. Mol Diagn Ther. 2012;16(2):79-92. 
2. Wharton SB, O'Callaghan JP, Savva GM, et al. Population variation in glial fibrillary acidic protein levels in brain ageing: relationship to Alzheimer-type pathology and dementia. Dement Geriatr Cogn Disord. 2009;27(5):465-473.
3. C.C. Yang, S.Y. Yang, C. S. Ho, et al., "Development of antibody functionalized magnetic nanoparticles for the immunoassay of carcinoembryonic antigen: a feasibility study for clinical use" J Nanobiotechnology. 12: 44. 2014.